Quantization of CD34+ peripheral blood hematopoietic progenitors for autografting in cancer patients

M. Di Nicola, S. Siena, M. Bregni, F. Peccatori, M. Magni, F. Ravagnani, L. Zorzino, G. Bonadonna, A. M. Gianni

Research output: Contribution to journalArticlepeer-review

Abstract

After myeloablative regimens, combined reinfusion of peripheral blood hematopoietic circulating progenitor cells (CPC) and bone marrow, yields a very rapid hematopoietic recovery. Therefore, based on the knowledge that CPC express the CD34 and CD33 differentiation antigen, we have developed a direct immunofluorescence flow cytometry assay to detect the peak of CPC in the peripheral blood of patients treated with high dose chemotherapy and growth factors. This assay, compared to CFU-GM assay, has the following advantages: 1) easy to do 2) standardized method 3) real time information on CPC number. This work illustrates the practical aspects of this assay and substantiate the widespread use of the CD34/33 flow cytometry assay to guide harvesting of circulating hematopoietic progenitors for autologous transplantation.

Original languageEnglish
Pages (from-to)80-82
Number of pages3
JournalInternational Journal of Artificial Organs
Volume16
Issue numberSUPPL. 5
Publication statusPublished - 1993

ASJC Scopus subject areas

  • Biophysics

Fingerprint Dive into the research topics of 'Quantization of CD34+ peripheral blood hematopoietic progenitors for autografting in cancer patients'. Together they form a unique fingerprint.

Cite this